X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to support the DIOSynVax product DIOS-HFVac3 vaccine for clinical advancement. It is being evaluated in the preclinical trial studies for the treatment of viral hemorrhagic fevers.
Lead Product(s): DIOS-HFVac3
Therapeutic Area: Infections and Infectious Diseases Product Name: DIOS-HFVac3
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: DIOSynVax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2024
Details:
Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting.
Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: Nous-209
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Nouscom AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
ProBioGen and ImmunOs extends their partnership for further large-scale manufacturing of clinical material for IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, ImmunOs' lead program for the treatment of cancer.
Lead Product(s): IOS-1002,Pembrolizumab
Therapeutic Area: Oncology Product Name: IOS-1002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ImmunOs Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 12, 2023
Details:
VAC85135, an investigational viral vector-based cancer vaccine for hematological malignancies. The MVA-based component of the vaccine was produced using ProBioGen's AGE1.CR.pIX.
Lead Product(s): VAC85135,Ipilimumab
Therapeutic Area: Oncology Product Name: VAC85135
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
ProBioGen to provide cell line development, process development and GMP manufacturing at 1000 L bioreactor scale of Asher's lead immuno-oncology candidate, AB248.
Lead Product(s): AB248
Therapeutic Area: Oncology Product Name: AB248
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Asher Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 26, 2021
Details:
The unique advantage of the GlymaxX® technology is that a single GlymaxX® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level.
Lead Product(s): Afucosylated antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2021
Details:
ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT® cell line expression platform, incl over process development till GMP manufacturing of the mAb intermediates of Heidelberg Pharma’s ATAC molecules for cancer indications.
Lead Product(s): Antibody-targeted Amanitin-Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Heidelberg Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 22, 2020
Details:
Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a ?? T-cell engaging bispecific antibody format.
Lead Product(s): Vγ9Vδ2 T cells based antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Lava Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2020
Details:
ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.
Lead Product(s): GlymaxX
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
